Identifying robust and sensitive biomarkers during preclinical discovery can help to predict drug efficacy and improve clinical translation. Moreover, profiling established clinical biomarkers in cellular and animal models of disease can be used to confirm the translational relevance of preclinical research.

Our molecular biomarker services can be linked to any of our in vitro assays or in vivo models and our team of experts are available to assist you in designing bespoke protocols to achieve your objectives. Partnerships with biobanks and clinical research centres provides access to tissue, fluids, and clinical histories to assist clinical biomarker discovery.

Cutting-edge and high-performance electrochemiluminescence (MESO SCALE DISCOVERY - MESO® QuickPlex SQ 120) and infrared (Licor Odyssey® CLx Imaging System) technologies facilitate the detection of proteins and phosphoproteins in rodent, canine, non-human primate, and human samples. Our imaging technologies include light, fluorescent and confocal microscopy, supporting histological techniques including immunohistochemistry (IHC), immunofluorescence and immunocytochemistry (ICC).

All our protocols can be customised to detect your proteins of interest.

Examples of models we offer:

  • •
    Cytokine and chemokine signalling
  • •
    NLRP3 inflammasome signalling
  • •
    Microglia activation: activation markers, cell morphology
  • •
    Stereology cell counting: tyrosine hydroxylase (TH) positive cells, Iba1 positive cells
  • •
    Disease relevant proteins: TAU, p-TAU, amyloid-beta, alpha-synuclein
  • •
    Synaptic plasticity: neurite outgrowth, dendritic complexity, synaptic protein expression
  • •
    Neurotrophins: BDNF
  • •
    Intracellular signalling: protein kinases, phosphoproteins